Literature DB >> 15984952

Mucosal disease series. Number III. Mucous membrane pemphigoid.

J Bagan1, L Lo Muzio, L L Muzio, C Scully.   

Abstract

Mucous membrane pemphigoid (MMP) is a sub-epithelial vesiculobullous disorder. It is now quite evident that a number of sub-epithelial vesiculobullous disorders may produce similar clinical pictures, and also that a range of variants of MMP exist, with antibodies directed against various hemidesmosomal components or components of the epithelial basement membrane. The term immune-mediated sub-epithelial blistering diseases (IMSEBD) has therefore been used. Immunological differences may account for the significant differences in their clinical presentation and responses to therapy, but unfortunately data on this are few. The diagnosis and management of IMSEBD on clinical grounds alone is impossible and a full history, general, and oral examination, and biopsy with immunostaining are now invariably required, sometimes supplemented with other investigations. No single treatment regimen reliably controls all these disorders, and it is not known if the specific subsets of MMP will respond to different drugs. Currently, apart from improving oral hygiene, immunomodulatory-especially immunosuppressive-therapy is typically used to control oral lesions. The present paper reviews pemphigoid, describing the present understanding of this fascinating clinical phenotype, summarising the increasing number of subsets with sometimes-different natural histories and immunological features, and outlining current clinical practice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15984952     DOI: 10.1111/j.1601-0825.2005.01140.x

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  8 in total

1.  Comparison of reactivity and epitope recognition between sera from American and Italian patients with oral pemphigoid.

Authors:  M Mignogna; A Lanza; L Rossiello; V Ruocco; A R Ahmed
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

2.  Oral mucous membrane pemphigoid in a group of Thai patients-A 15-year retrospective study.

Authors:  Waranun Buajeeb; Kununya Pimolbutr; Naruemon Panpradit; Nis Okuma
Journal:  J Dent Sci       Date:  2021-11-24       Impact factor: 3.719

Review 3.  The Differential Diagnosis of Desquamative Gingivitis: Review of the Literature and Clinical Guide for Dental Undergraduates.

Authors:  Faris Al-Abeedi; Yaser Aldahish; Zaid Almotawa; Omar Kujan
Journal:  J Int Oral Health       Date:  2015

4.  Chronic desquamative gingivitis in siblings: A report of two cases.

Authors:  Harshad N Vijayakar; Pratik P Shah; Ankit B Desai; Sugandha R Ghonasgi; Ravindra J Gawankar
Journal:  J Indian Soc Periodontol       Date:  2014-05

5.  Oral mucous membrane pemphigoid - Two case reports with varied clinical presentation.

Authors:  Sreedevi Dharman; Arvind Muthukrishnan
Journal:  J Indian Soc Periodontol       Date:  2016 Nov-Dec

Review 6.  Adverse Immunologically Mediated Oral Mucosal Reactions to Systemic Medication: Lichenoid Tissue Reaction/Interface Dermatitis-Stomatitis, Autoimmune Vesiculobullous Disease, and IgE-Dependent and Immune Complex Reactions.

Authors:  R A G Khammissa; R Chandran; A Masilana; J Lemmer; L Feller
Journal:  J Immunol Res       Date:  2018-06-10       Impact factor: 4.818

7.  Desquamative gingivitis - A clinical sign in mucous membrane pemphigoid: Report of a case and review of literature.

Authors:  Shamimul Hasan
Journal:  J Pharm Bioallied Sci       Date:  2014-04

8.  European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II.

Authors:  E Schmidt; H Rashid; A V Marzano; A Lamberts; G Di Zenzo; G F H Diercks; S Alberti-Violetti; R J Barry; L Borradori; M Caproni; B Carey; M Carrozzo; G Cianchini; A Corrà; F G Dikkers; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; S Rauz; B D van Rhijn; M Roth; J Setterfield; D Zillikens; G Zambruno; B Horváth; F Caux
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-26       Impact factor: 6.166

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.